Year archive

Cutia Therapeutics — 2024 filings

All 78 regulatory filings released by Cutia Therapeutics (2487) in 2024, sourced directly from the official regulator.

78 Filings

2024 Period

2024 filings (78)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION IN CHINA Regulatory Filings	2024-12-30	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024 Regulatory Filings	2024-12-05	English
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION REACHED PRIMARY ENDPOINT Regulatory Filings	2024-11-28	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA WERE PRESENTED AT THE 19T Regulatory Filings	2024-11-28	English
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-11-18	English
VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2024-11-11	English
VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-11-11	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024 Regulatory Filings	2024-11-01	English
OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024 Regulatory Filings	2024-10-31	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-30	English
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK Regulatory Filings	2024-10-30	English
Next Day Disclosure Return Regulatory Filings	2024-10-22	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-21	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-18	English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-10-17	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-17	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-15	English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-10-14	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-10	English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-10-09	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-09	English
VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY THE CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR Director's Dealing	2024-10-08	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-08	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Regulatory Filings	2024-10-04	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-04	English
Next Day Disclosure Return Transaction in Own Shares	2024-10-03	English
VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION Regulatory Filings	2024-09-30	English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS Regulatory Filings	2024-09-27	English
Next Day Disclosure Return Transaction in Own Shares	2024-09-27	English
2024 Interim Report Interim / Quarterly Report	2024-09-26	English
Next Day Disclosure Return Transaction in Own Shares	2024-09-26	English
Next Day Disclosure Return Transaction in Own Shares	2024-09-25	English
Next Day Disclosure Return Transaction in Own Shares	2024-09-23	English
Next Day Disclosure Return Transaction in Own Shares	2024-09-20	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024 Regulatory Filings	2024-09-04	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2023 ANNUAL REPORT Regulatory Filings	2024-09-02	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 Interim / Quarterly Report	2024-08-29	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 8TH ANNUAL MEETING OF CHINESE HAIR RESEARCH SO Regulatory Filings	2024-08-29	English
DATE OF BOARD MEETING Report Publication Announcement	2024-08-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024 Share Issue/Capital Change	2024-08-05	English
VOLUNTARY ANNOUNCEMENT - DRUG MARKETING AUTHORIZATION APPLICATION FOR CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2024-07-31	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED ONLINE IN THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY Regulatory Filings	2024-07-30	English
Next Day Disclosure Return Transaction in Own Shares	2024-07-23	English
Next Day Disclosure Return Transaction in Own Shares	2024-07-18	English
Next Day Disclosure Return Transaction in Own Shares	2024-07-17	English
Next Day Disclosure Return Transaction in Own Shares	2024-07-16	English
VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PROGRAM UNDER THE SHARE REPURCHASE MANDATE Capital/Financing Update	2024-07-12	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-07-03	English
VOLUNTARY ANNOUNCEMENT - LAST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION Regulatory Filings	2024-06-28	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC ACCEPTED FOR E-POSTER PRESENTATION AT THE 29TH ANNUAL MEETING OF CSD Regulatory Filings	2024-06-28	English
OPERATIONAL UPDATE FOR THE FIRST QUARTER OF 2024 Regulatory Filings	2024-06-27	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024 Regulatory Filings	2024-06-05	English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIAL OF CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PRESENTED AT THE 13TH ADC Regulatory Filings	2024-05-31	English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS APPROVED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL Regulatory Filings	2024-05-30	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024 Regulatory Filings	2024-05-06	English
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) IN HONG KONG, PRC Regulatory Filings	2024-04-30	English
VOLUNTARY ANNOUNCEMENT - A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY OBTAINED THE "DRUG MANUFACTURING CERTIFICATE" ISSUED BY THE JIANGSU MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2024-04-30	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON WEDNESDAY, 5 JUNE 2024 AGM Information	2024-04-26	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2024-04-26	English
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES (3) PROPOSED RE-APPOINTMENT OF AUDITOR AND (4) NOTICE OF ANNUAL GENERA AGM Information	2024-04-26	English
2023 Environmental, Social and Governance Report Environmental & Social Information	2024-04-26	English
2023 Annual Report Annual Report	2024-04-26	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024 Regulatory Filings	2024-04-05	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 Annual Report	2024-03-27	English
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION OF CU-10101 (TOPICAL NOVEL SMALL MOLECULE AGENT) FOR ATOPIC DERMATITIS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL Regulatory Filings	2024-03-26	English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN FTSE GLOBAL EQUITY INDEX SERIES Regulatory Filings	2024-03-18	English
DATE OF BOARD MEETING Report Publication Announcement	2024-03-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 Regulatory Filings	2024-03-06	English
OPERATIONAL UPDATE FOR THE YEAR ENDED 31 DECEMBER 2023 AND FOURTH QUARTER OF 2023 Regulatory Filings	2024-02-28	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION IN CHINA Regulatory Filings	2024-02-27	English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES Regulatory Filings	2024-02-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 Share Issue/Capital Change	2024-02-06	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-40102 (TOPICAL FINASTERIDE SPRAY) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION Regulatory Filings	2024-01-30	English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) IN CHINA REACHED PRIMARY ENDPOINT Regulatory Filings	2024-01-30	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 Regulatory Filings	2024-01-04	English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR SUBMENTAL ADIPOSE ACCUMULATION Regulatory Filings	2024-01-02	English